Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART.

Published

Journal Article

Over 700 patients with HIV-associated wasting while receiving HAART were randomly assigned to double-blind treatment for 12 weeks with recombinant human growth hormone (rhGH) daily or on alternate days, or to placebo. Maximum exercise intensity increased by a median of 2.35kJ in the alternate-days group and 2.60 kJ in the daily group but decreased by 0.25kJ in the placebo group. The median difference between the daily and placebo groups was 2.85 kJ (P < .0001). These improvements suggest that rhGH treatment may enable patients with wasting to perform activities of daily living that would be exhausting without rhGH treatment.

Full Text

Duke Authors

Cited Authors

  • Evans, WJ; Kotler, DP; Staszewski, S; Griffin, GE; Isgaard, J; Gertner, JM; O'Brien, F; Svanberg, E

Published Date

  • June 2005

Published In

Volume / Issue

  • 15 / 6

Start / End Page

  • 301 - 314

PubMed ID

  • 15962453

Pubmed Central ID

  • 15962453

International Standard Serial Number (ISSN)

  • 1053-0894

Language

  • eng

Conference Location

  • United States